TrialJournal of clinical oncology : official journal of the American Society of Clinical Oncology2017

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).

Solange Peters et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.